18F-PEG-biotin: Precursor (boroaryl-PEG-biotin) synthesis, 18F-labelling and an in-vitro assessment of its binding with NeutravidinTM-trastuzumab pre-treated cells

Applied Radiation and Isotopes

Volumn 69, Issue 10, 2011, Pages 1395-1400

  Smith, Tim A D ^a   Simpson, Michael ^a   Cheyne, Richard ^a   Trembleau, Laurent ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

18F; Biotin; Breast cancer cells; NeutravidinTM; PET

Indexed keywords

18F; ANTIBODY CONJUGATE; BIOTIN; BREAST CANCER CELLS; IMAGING CELLS; IN-VITRO; NEUTRAVIDIN; NUCLEAR DECAYS; RESIDENCE TIME; SHORT-LIVED NUCLIDES; TRASTUZUMAB;

BIOSYNTHESIS; CELL MEMBRANES; FLUORINE; ISOTOPES; MONOCLONAL ANTIBODIES; SOLUTIONS;

COENZYMES;

AVIDIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORO POLYETHYLENEGLYCOL BIOTIN F 18; NEUTRAVIDIN; TRACER; TRASTUZUMAB; UNCLASSIFIED DRUG; WATER; BIOTIN; BORON DERIVATIVE; DRUG DERIVATIVE; FLUORINE; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY;

ACIDIFICATION; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; FLUORINATION; IN VITRO STUDY; ISOTOPE LABELING; ISOTOPE TRACING; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; FEMALE; HUMAN; METABOLISM; METHODOLOGY; SYNTHESIS; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; AVIDIN; BIOTIN; BORON COMPOUNDS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; ISOTOPE LABELING; POLYETHYLENE GLYCOLS; RECEPTOR, ERBB-2;

EID: 79960958959     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2011.05.005     Document Type: Article

References (17)

1. Breitz H.B., Weiden P.L., Beaumier P.L., Axworthy D.B., Seiler C., Su F.M., et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and Y-90-DOTA-biotin. J. Nucl. Med. 2000, 41:131-140.
2. Coenen H.H., Elsinga P.H., Iwata R., Kilbourn M.R., Pillai M.R.A., Rajan M.G.R., Wagner H.N., Zaknun J.J. Fluorine-18 radiopharmaceuticals beyond [F-18]FDG for use in oncology and neurosciences. Nucl. Med. Biol. 2010, 37:727-740.
3. Goldenberg D.M., Starkey R.M., Paganelli G., Barbet J., Chatal J.-F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 2006, 5:823-834.
4. Griffiths G.L., Chang C.H., McBride W.J., Rossi E.A., Sheerin A., Tejada G.R., et al. Reagents and methods for PET using bispecific antibody pretargeting and Ga-68-radiolabeled bivalent hapten-peptide-chelate conjugates. J. Nucl. Med. 2004, 45:30-39.
5. Harwig C.W., Ting R., Adam M.J., Ruth T.J., Perrin D.M. Synthesis and characterization of 2,6-difluoro-4-carboxyphenylboronic acid and a biotin derivative thereof as captors of anionic aqueous [F-18]-fluoride for the preparation of [F-18/F-19]-labeled aryltrifluoroborates with high kinetic stability. Tetrahedron Lett. 2008, 49:3152-3156.
6. Kleine L.G., Solano M., Rusckowski M., Hunt K.E., Johnson K.L., Kirker-Head C.A. Evaluation of technetium Tc 99m-labeled biotin for scintigraphic detection of soft tissue inflammation in horses. Am. J. Vet. Res. 2008, 69:639-646.
7. Lazzeri E., Pauwels E.K.J., Erba P.A., Volterrani D., Manca M., Bodei L., et al. Clinical feasibility of two-step streptavidin/In-111-biotin scintigraphy in patients with suspected vertebral osteomyelitis. Eur. J. Nucl. Med. Mol. Imaging 2004, 31:1505-1511.
8. Lewis M.R., Wang M., Axworthy D.B., Theodore L.J., Mallet R.W., Fritzberg A.R., et al. In-vivo evaluation of pretargeted Cu-64 for tumor imaging and therapy. J. Nucl. Med. 2003, 44:1284-1292.
9. Marttila A.T., Laitinen O.H., Airenne K.J., Kulik T., Bayer E.A., Wilchek M., Kulomaa M.S. Recombinant NeutraLite avidin: a non-glycosylated, acidic mutant of chicken avidin that exhibits high affinity for biotin and low non-specific binding properties. FEBS Lett. 2000, 467:31-36.
10. Pratesi A., Bucelli F., Mori I., Chinol M., Verdoliva A., Paganelli G., et al. Biotin derivatives carrying two chelating DOTA units. Synthesis, in vitro evaluation of biotinidases resistance, avidin binding, and radiolabeling tests. J. Med. Chem. 2010, 53:432-440.
11. Rusnak D.W., Alligood K.J., Mullin R.J., Spehar G.M., Arenas-Elliott C., Martin A.M., Degenhardt Y., et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib in an expanded panel of human normal and tumour cell. Cell Prolif. 2007, 40:580-594.
12. Shoup T.M., Fischman A.J., Jaywook S., Babich J.W., Strauss H.W., Elmaleh D.R. Synthesis of fluorine-18-labeled biotin derivatives-biodistribution and infection localization. J. Nucl. Med. 1994, 35:1685-1690.
13. Simpson, M., Trembleau, L., Cheyne, R.W., Smith, T.A.D., 2011. One pot production of 18F-biotin by conjugation with 18F-FDG for pre-targeted imaging: synthesis and radio-labelling of a pegylated precursor. Appl. Radiat. Isotopes 69, 418-422.
14. Ting R., Adam M.J., Ruth T.J., Perrin D.M. Arylfluoroborates and alkylfluorosilicates as potential PET imaging agents: high-yielding aqueous biomolecular F-18-labeling. J. Am. Chem. Soc. 2005, 127:13094-13095.
15. Ting R., Harwig C., auf dem Keller U., McCormick S., Austin P., Overall C.M., et al. Toward [F-18]-labeled aryltrifluoroborate radiotracers: in vivo positron emission tomography imaging of stable aryltrifluoroborate clearance in mice. J. Am. Chem. Soc. 2008, 130:12045-12055.
16. Wartlick H., Michaelis K., Balthasar S., Strebhardt K., Kreuter J., Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J. Drug Target. 2004, 12:461-471.
17. Wu A.M., Chen W.G., Raubitschek A., Williams L.E., Neumaier M., Fischer R., et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 1996, 2:21-36.